ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the controversy surrounding FDA-approved treatments for geographic atrophy.
Two treatments are commercially available, but Kim, professor of ophthalmology at Vanderbilt Eye Institute, said the drugs are invasive and expensive, have side effects, and “don’t provide any meaningful visual function benefit.”
“They have some ability to modestly slow the rate of progression of the disease, but it hasn’t translated into any meaningful visual benefit that the patient can sense,” he said.